Roberts, Glore & Co’s Eli Lilly LLY Stock Holding History

Roberts, Glore & Co’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$545K	Sell	592 -1	-0.2%	-$1.01K	0.15%	125
2025 Q4	$637K	Sell	593 -35	-6%	-$33.5K	0.17%	116
2025 Q3	$479K	Buy	628 +7	+1%	+$5.21K	0.13%	138
2025 Q2	$484K	Hold	621	–	–	0.14%	132
2025 Q1	$513K	Buy	621 +13	+2%	+$10.8K	0.16%	123
2024 Q4	$469K	Sell	608 -5	-0.8%	-$4.14K	0.14%	126
2024 Q3	$543K	Sell	613 -2	-0.3%	-$1.8K	0.16%	121
2024 Q2	$557K	Sell	615 -10	-2%	-$8K	0.17%	116
2024 Q1	$486K	Sell	625 -2	-0.3%	-$1.42K	0.15%	120
2023 Q4	$365K	Buy	627 +30	+5%	+$17.5K	0.11%	136
2023 Q3	$321K	Buy	597 +25	+4%	+$12.9K	0.11%	148
2023 Q2	$268K	Sell	572 -20	-3%	-$8.39K	0.09%	170
2023 Q1	$203K	Buy	+592	New	+$200K	0.07%	194
2022 Q1	–	Sell	-735	Closed	-$203K	–	208
2021 Q4	$203K	Buy	+735	New	+$186K	0.05%	202

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Roberts, Glore & Co's LLY Position: Q1 2026 in Review

Roberts, Glore & Co reduced its Eli Lilly (LLY) stake by 0.17% in Q1 2026, selling an estimated $1.01K and leaving 592 shares worth $545K. The position accounts for 0.15% of the portfolio, ranked #125.

Roberts, Glore & Co first reported a position in LLY in Q4 2021 and has held it in 14 quarters since. The position peaked at $637K in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

Roberts, Glore & Co held 592 shares of Eli Lilly worth $545K as of Q1 2026.
Roberts, Glore & Co sold 1 Eli Lilly share in Q1 2026, an estimated $1.01K.
Eli Lilly made up 0.15% of Roberts, Glore & Co's portfolio in Q1 2026, its #125 holding.
Roberts, Glore & Co first reported a position in Eli Lilly in Q4 2021 and has held it in 14 quarters since.
Roberts, Glore & Co's Eli Lilly position peaked at $637K in Q4 2025.
4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Roberts, Glore & Co's 13F filing for Q1 2026, filed 4 May 2026.